|Bid||33.97 x 100|
|Ask||34.14 x 100|
|Day's Range||33.97 - 34.21|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.65|
|Dividend & Yield||1.28 (3.75%)|
|1y Target Est||N/A|
Each year, more than 23,000 people die in the U.S. as a result of bacterial infections that are resistant to antibiotics – the equivalent of a Boeing 747 crashing each week. Worse, there are at least 2 million people each year who acquire serious infections by bacteria resistant to antibiotics.
When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here's why.
But it would have been nice to have been able to keep these drugs in-house and bring them to market under the Pfizer banner.